PharmaJet Inc. is expanding its needle-free injection technology by developing self-injection pens designed for home use. These pens will allow for precise administration of various pharmaceuticals without the need for traditional needles.
The injectors are targeted at chronic disease and metabolic peptide markets and are currently undergoing early testing. By offering a needle-free option, PharmaJet aims to address common issues such as needle aversion and injection pain, which can hinder patient compliance.
The reusable design of these injector pens may also reduce waste compared to disposable alternatives, making them a more eco-friendly choice. PharmaJet has already successfully used its technology to administer over 12 million vaccine injections globally.
“We are excited about the prospect of entering the pen injector market with the PharmaJet needle-free self-injector pens,” said Wouter Latour, president and CEO of PharmaJet. The Golden-based company plans to collaborate with industry partners to further enhance its offerings in the growing metabolic peptide segment and other markets that require frequent injections.
